2020health's Interim Report on Value-based Pricing

Improving Patient Outcomes: How can Value-based Pricing
improve access and adoption of new treatments?

How we value medicines and the pricing of new medical treatments, both new medicines and medical technologies, is crucial to the health of the UK. Not only the physical health of the public but also the economical health of the nation and the scientific health of the UK based research and development industry.

This publication was inspired by the political, clinical and industry interest shown in the Office of Fair Trading 2007 report into ‘Value Based Pricing (VBP)’. We wanted to explore further the concept of what ‘Value’ actually means, how VBP is perceived and defined. In order to do this we undertook extensive interviews with stakeholders and had a web-based questionnaire open to all interested parties. This interim report details our findings and makes recommendations based on them.